Media coverage about Otonomy (NASDAQ:OTIC) has trended somewhat positive on Thursday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Otonomy earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.6304619441187 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Otonomy (NASDAQ:OTIC) remained flat at $$5.05 during midday trading on Thursday. The company had a trading volume of 361,800 shares, compared to its average volume of 805,125. Otonomy has a one year low of $2.80 and a one year high of $21.15.
Otonomy (NASDAQ:OTIC) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.15. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.43 million. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. The business’s quarterly revenue was down 12.8% on a year-over-year basis. analysts forecast that Otonomy will post -2.88 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Otonomy (OTIC) Earns Daily News Impact Score of 0.07” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/14/otonomy-otic-earns-daily-news-impact-score-of-0-07.html.
Otonomy Company Profile
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
What are top analysts saying about Otonomy? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Otonomy and related companies.